InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
August 06 2008 - 9:00AM
PR Newswire (US)
BRITISH COLUMBIA, Canada, Aug. 6 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc., (TSX VENTURE: IXS.V; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com/), a drug development company
commercializing the next generation of monoclonal antibodies based
on its Dynamic Cross Linking (DXL(TM)) technology, today announced
the addition of a new product designated DXLr120 (CD20). This is
the third product added to the growing InNexus pipeline and was
developed using new recombinant methods to produce a DXL(TM) anti
CD20 antibody. InNexus' first and second products were developed
with chemical methods to impart DXL(TM) into the development of new
antibodies and the latest product represents a significant patent
expansion for the company. InNexus Chief Scientific Officer, Dr.
Thomas Kindt, said, "Within the past two years, InNexus has moved
rapidly to accelerate preclinical development of multiple
candidates. Use of recombinant methods to develop DXLr120 with our
patented DXL(TM) technology demonstrates the expertise of our team
and the opportunity we have to create multiple therapeutic and
diagnostic antibodies." DXLr120 significantly improves antibodies
binding to CD20, the target for Non Hodgkin's Lymphoma and
Rheumatoid Arthritis and joins InNexus' well-studied DXL625 (CD20).
DXL625, developed with chemical methods, also significantly
improves the binding of antibodies to CD20 and increases potency
using both in vitro and in vivo studies. Preliminary data for
DXLr120 already reveals properties akin to those shown for DXL625.
Plans are underway to subject DXLr120 to the full battery of tests
for potency, in vivo efficacy and safety used for DXL625. The
company will present at IBC's 13th Annual World Congress Drug
Discovery & Development of Innovative Therapeutics (DDT)
Conference in Boston at the World Trade Center Boston. The InNexus
presentation will be within the Main Conference (amphitheater)
beginning at 9:40 AM (ET) on Wednesday, August 6th. Jeff Morhet,
Chief Executive Officer and Dr. Thomas Kindt, Chief Scientific
Officer will present an in-depth presentation of a Case Study of
InNexus' preclinical candidate DXL625 (CD20): A New Platform for
Augmenting Antibody Therapeutics for Cancer. About Recombinant
Antibodies Antibodies are protein molecules produced by our immune
system. The shape of an antibody is often described in a Y shape
and one of their critical roles is to recognize and attack foreign
bacteria and viruses. Antibodies come in numerous forms and each
type can recognize unique antigen (targets). Each arm of the
antibody (upper portion of the Y) has unique molecular structure
(keys) that combine with the targets. Attachment of many antibodies
to an object with these targets ultimately causes its destruction.
Recombinant technologies have seen an explosion in use as
manufacturing procedures have streamlined with shortened time
frames and the final product often has a greater quality than that
of products from non-recombinant methods. About InNexus InNexus is
a drug development company commercializing the next generation of
monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of existing antibody products while opening
new markets and disease applications. DXL(TM) antibodies utilize
unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal
management based in Scottsdale, Arizona on the campus of Mayo
Clinic and has its own in-house developmental facilities. These
development resources provide validation of protein and peptide
discoveries, enabling InNexus (and its strategic partners) to
advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com/. The TSX Venture
Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this news release. This news release
may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are
subject to factors, many of which are beyond the Company's control,
that may cause actual results or performance to differ materially
from those currently anticipated in such statements. DATASOURCE:
InNexus Biotechnology Inc. CONTACT: Jeff Morhet, Chairman &
Chief Executive Officer, or Dr. Thomas Kindt, Chief Scientific
Officer, both of InNexus Biotechnology Inc., +1-480-862-7500 Web
site: http://www.ixsbio.com/
Copyright